ARQT News and Press, Arcutis Biotherapeutics Inc. From 05/04/21

Arcutis Biotherapeutics (ARQT): Q1 GAAP EPS of -$0.76 beats by $0.26.Cash, cash equivalents, restricted cash and marketable securities of $446.5MPress Release For further details see: Arcutis Biotherapeutics EPS beats by $0.26

New Drug Application (NDA) submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021 Positive Phase 3 results for topical roflumilast cream in plaque psoriasis announced in February Advancing topical roflumilast f...

Presentation will highlight efficacy and safety data from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream ( ARQ-151 ) as a potential topical once-daily treatment for chronic plaque psoriasis WESTLAKE VILLAGE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- ...

Gainers: Brooklyn ImmunoTherapeutics (BTX) +38%, Motus GI MOTS +32%, CryoLife (CRY) +16%, Mesoblast MESO +14%, Arcutis Biotherapeutics (ARQT) +10%.Losers: Ardelyx (ARDX) -13%, Pacific Biosciences of California (PACB) -13%, ALX Oncolo...

Image Sensing Systems (ISNS) +24% on strategic changes.Motus GI Holdings (MOTS) +47% on FDA 510(k) clearance of Pure-Vu System.Tarena International (TEDU) +10% after entering "going private" merger agreement.Salem Media Group (SALM) +9%.Arcutis Biotherapeutics (ARQT) +8%.Mesobl...

WESTLAKE VILLAGE, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-der...

Detailed results from Phase 2b study of roflumilast foam in scalp and body psoriasis featured in late-breaking oral presentation Data demonstrate roflumilast foam was well-tolerated and improved scalp and body psoriasis as early as two weeks after treatment initiation Fo...

WESTLAKE VILLAGE, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-der...

Arcutis Biotherapeutics (ARQT) initiates a pivotal Phase 3 clinical trial evaluating topical roflumilast cream (ARQ-151) as a potential treatment for mild-to-moderate atopic dermatitis ((AD)) in patients between the ages of 2 and 5 years.Roflumilast cream is a once daily t...

Roflumilast cream potential “Best in Class” topical PDE4 inhibitor Atopic dermatitis affects approximately 19 million patients in the U.S. The Company anticipates topline data in the second half of 2022 WESTLAKE VILLAGE, Calif., April 12, 2021 (GLOBE NEWSWIRE...